Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(66.7%)

Phase 3

1(16.7%)

N/A

1(16.7%)

6Total

Phase 4(4)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02417571Not ApplicableUnknown

Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD

Role: collaborator

NCT02580474Phase 4Completed

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Role: collaborator

NCT03357653Phase 3Unknown

Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

Role: collaborator

NCT02459353Phase 4Completed

Effect of Dapagliflozin on Glycemic Variability

Role: collaborator

NCT01554007Unknown

Clinical Course of Korean Crohn's Disease Cohort

Role: collaborator

NCT01871792Phase 4Unknown

Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction

Role: collaborator

NCT00532597Phase 4Unknown

Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients

Role: lead

All 7 trials loaded